{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:05:06Z","timestamp":1780329906053,"version":"3.54.1"},"reference-count":68,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Antibody-drug conjugates (ADCs), including enfortumab vedotin, disitamab vedotin, and sacituzumab govitecan, are altering the therapeutic landscape for locally advanced or metastatic urothelial carcinoma (la\/mUC). Comprehensive comparative evidence evaluating their translation in the clinical setting and modifying clinical covariates is required.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To synthesize multidimensional evidence from interventional and observational settings to evaluate clinical outcomes, define the evolving therapeutic positioning of enfortumab vedotin, disitamab vedotin, and sacituzumab govitecan, and identify drivers of heterogeneity through meta-regression.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar were searched from database inception to October 23, 2025.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Interventional and observational studies of adults with la\/mUC treated with enfortumab vedotin, disitamab vedotin, or sacituzumab govitecan.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Independent reviewers extracted data following PRISMA guidelines. A rigorous metadata deduplication algorithm prevented patient double-counting. Random-effects models pooled data. Bayesian network meta-analysis (NMA) used reconstructed individual patient data. Inverse-variance weighted meta-regression assessed clinical covariates.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were disease control rate, objective response rate (ORR), and clinical complete response.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty independent studies involving 6085 patients were included. For enfortumab vedotin monotherapy, the pooled ORR was 43.9% (95% CI, 40.4%-47.5%) in interventional studies and 44.6% (95% CI, 41.0%-48.2%) in observational cohorts. For enfortumab vedotin plus pembrolizumab, interventional cohorts were associated with a pooled ORR of 67.5% (95% CI, 63.5%-71.3%) overall and 65.4% (95% CI, 60.0%-70.5%) in cisplatin-ineligible patients. Furthermore, disitamab vedotin plus programmed cell death protein 1 (PD-1) inhibitors was associated with an ORR of 74.7% (95% CI, 69.4%-79.4%) in interventional trials and 61.7% (95% CI, 52.6%-70.1%) observationally. Meta-regression identified prior PD-1\/L1 exposure (\u03b2\u2009=\u2009\u22120.071;\n P<\/jats:italic>\n \u2009=\u2009.003) and treatment regimen (\u03b2\u2009=\u2009\u22120.890;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) as factors associated with primary response. Notably, the pure randomized clinical trial network meta-analysis of first-line treatments for cisplatin-ineligible patients revealed that enfortumab vedotin monotherapy was associated with a statistically significant overall survival advantage over chemotherapy (HR, 0.50; 95% CI, 0.29-0.86; posterior probability &amp;gt;99%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this meta-analysis of ADCs for la\/mUC, enfortumab vedotin-based regimens were associated with robust outcomes across clinical settings, and disitamab vedotin combined with immunotherapy was associated with potent clinical activity. Meta-regression indicated that prior immunotherapy exposure and hepatic tumor burden were associated with attenuated treatment responses.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.14764","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:30:41Z","timestamp":1780327841000},"page":"e2614764","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langkun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhai","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"3","key":"zoi260425r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi260425r2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy.","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"zoi260425r3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines.","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"zoi260425r4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.2018.36.6_suppl.410","article-title":"Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator\u2019s choice (paclitaxel, docetaxel, or vinfluni ne) in recurrent, advanced urothelial cancer (UC).","volume":"36","author":"Bellmunt","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10122","key":"zoi260425r5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"zoi260425r6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi260425r7","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer.","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi260425r8","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models.","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"zoi260425r9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"key":"zoi260425r10","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00879","article-title":"Testing and Interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma.","volume":"9","author":"Koshkin","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"zoi260425r11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi260425r12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer.","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi260425r13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.19.02035","article-title":"Informing patients about expected outcomes: the efficacy-effectiveness gap.","volume":"38","author":"Templeton","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi260425r14","doi-asserted-by":"publisher","first-page":"S1150","DOI":"10.1016\/j.annonc.2024.08.2074","article-title":"1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and\/or diabetes mellitus (DM): a UNITE study analysis.","volume":"35","author":"Jang","year":"2024","journal-title":"Ann Oncol"},{"key":"zoi260425r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"zoi260425r16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"zoi260425r17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"zoi260425r18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis.","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"zoi260425r19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis.","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"issue":"11","key":"zoi260425r20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"issue":"25","key":"zoi260425r21","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer.","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi260425r22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial.","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi260425r23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma.","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi260425r24","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy.","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi260425r25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70368","article-title":"Phase 2 trial of enfortumab vedotin in patients with previously treated locally advanced or metastatic urothelial carcinoma in China.","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"zoi260425r26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.","volume":"29","author":"Taoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"zoi260425r27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1200\/JCO.2024.42.4_suppl.553","article-title":"Safety and efficacy of enfortumab vedotin in patients with metastatic\/ locally advanced urothelial cancer: real-world evidence from a European database.","volume":"42","author":"Zschaebitz","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260425r28","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.21873\/invivo.14075","article-title":"Outcomes of enfortumab vedotin treatment in patients ineligible for the EV-301 Trial.","volume":"39","author":"Nakamura","year":"2025","journal-title":"In Vivo"},{"key":"zoi260425r29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2147\/CMAR.S424070","article-title":"Effect of enfortumab vedotin dose adjustment on efficacy in metastatic urothelial carcinoma: a retrospective single-center experience.","volume":"15","author":"Clennon","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"2","key":"zoi260425r30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10585-025-10335-4","article-title":"Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study.","volume":"42","author":"Fiala","year":"2025","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"zoi260425r31","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s11255-025-04462-w","article-title":"Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma.","volume":"57","author":"Hara","year":"2025","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"zoi260425r32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/jjco\/hyae082","article-title":"Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study.","volume":"54","author":"Hayakawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"zoi260425r33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.21873\/cdp.10396","article-title":"Risk Classification of patients with advanced urothelial carcinoma treated with enfortumab vedotin.","volume":"4","author":"Ishikawa","year":"2024","journal-title":"Cancer Diagn Progn"},{"issue":"3","key":"zoi260425r34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s10147-024-02678-x","article-title":"Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma.","volume":"30","author":"Nakagawa","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"zoi260425r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab vedotin for metastatic urothelial carcinoma: comprehensive treatment outcomes and prognostic insights from a multicenter real-world study (YUSHIMA Study).","volume":"23","author":"Nakamura","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"zoi260425r36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10147-025-02709-1","article-title":"Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.","volume":"30","author":"Uchimoto","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"zoi260425r37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/jjco\/hyaf060","article-title":"Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study.","volume":"55","author":"Urabe","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"zoi260425r38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature.","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"zoi260425r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study.","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"zoi260425r40","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"zoi260425r41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1161089","article-title":"Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.","volume":"13","author":"Jindal","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"zoi260425r42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"zoi260425r43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer.","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi260425r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Enfortumab vedotin with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.","volume":"10","author":"Van Der Heijden","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"zoi260425r45","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial.","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi260425r46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"29","key":"zoi260425r47","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 cohort 2: a phase ii study of sacituzumab govitecan in cisplatin-ineligible patients with metastatic urothelial cancer progressing after previous checkpoint inhibitor therapy.","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi260425r48","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer.","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"zoi260425r49","doi-asserted-by":"publisher","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","article-title":"MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma: RC48G001 cohort C.","volume":"35","author":"Galsky","year":"1967","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi260425r50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study.","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260425r51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s12672-025-02362-0","article-title":"Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study.","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov Oncol"},{"issue":"12","key":"zoi260425r52","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1007\/s11255-025-04567-2","article-title":"A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis.","volume":"57","author":"Zhang","year":"2025","journal-title":"Int Urol Nephrol"},{"issue":"23","key":"zoi260425r53","doi-asserted-by":"publisher","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study.","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"zoi260425r54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study.","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi260425r55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12967-025-06237-4","article-title":"The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.","volume":"23","author":"Ge","year":"2025","journal-title":"J Transl Med"},{"issue":"7","key":"zoi260425r56","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"zoi260425r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102093","article-title":"RC48-antibody-drug conjugate in metastatic urothelial carcinoma: a multicenter real-world study in China.","volume":"22","author":"Chen","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"zoi260425r58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00345-025-05544-1","article-title":"Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.","volume":"43","author":"Yao","year":"2025","journal-title":"World J Urol"},{"key":"zoi260425r59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer.","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260425r60","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase ii clinical trials.","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi260425r61","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"key":"zoi260425r62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JCO.2025.43.5_suppl.665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: updated efficacy and safety results from the phase II RC4 8-C017 trial.","volume":"43","author":"Sheng","year":"2025","journal-title":"J Clin Oncol"},{"key":"zoi260425r63","doi-asserted-by":"publisher","first-page":"S1505","DOI":"10.1016\/j.annonc.2024.10.830","article-title":"LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): overall survival (OS) and safety analysis.","volume":"35","author":"Grivas","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi260425r65","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","article-title":"Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.","volume":"27","author":"Necchi","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi260425r66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi260425r67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer.","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"issue":"1","key":"zoi260425r68","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"zoi260425r64","unstructured":"Cigliola? A, Moschini? M, Tateo? V, . Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01\/02 interim results. American Society of Clinical Oncology. https:\/\/www.asco.org\/abstracts-presentations\/234415\/abstract"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849739\/zhang_2026_oi_260425_1779468471.50254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:30:44Z","timestamp":1780327844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849739"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.14764","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}